// App-Quantinova.ai

537 : Secukinumab, a Human AntiInterleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial

Researchers

Presenter

  • Alice B. Gottlieb

Principal Investigators

  • Philip J. Mease

  • Iain B. McInnes

  • Bruce Kirkham

  • Arthur Kavanaugh

  • Proton Rahman

  • Peter Nash

  • Luminita Pricop

  • Jiacheng Yuan

  • Hanno Richards

  • Shephard Mpofu

Medical Centers

  • Tufts Medical Center, Boston, MA

  • UCSD School of Medicine, La Jolla, CA

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Faculty of Medicine, Memorial University of Newfoundland, St. Johns, NF, Canada

  • The University of Queensland, Brisbane, Australia

Locations

  • United States

  • Canada

  • United Kingdom

  • Australia

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Psoriatic arthritis

  • Psoriasis

  • Acquired idiopathic generalized anhidrosis

  • Nonalcoholic steatohepatitis

Biomarkers

  • Cluster of differentiation 95

  • High sensitivity C-reactive protein

  • Interleukin 17A

  • RNA-binding protein FUS/TLS

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved